EA201291335A1 - Фармацевтические композиции для местного применения - Google Patents

Фармацевтические композиции для местного применения

Info

Publication number
EA201291335A1
EA201291335A1 EA201291335A EA201291335A EA201291335A1 EA 201291335 A1 EA201291335 A1 EA 201291335A1 EA 201291335 A EA201291335 A EA 201291335A EA 201291335 A EA201291335 A EA 201291335A EA 201291335 A1 EA201291335 A1 EA 201291335A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
local application
compositions
safely
diseases
Prior art date
Application number
EA201291335A
Other languages
English (en)
Other versions
EA022967B1 (ru
Inventor
Фритьоф Эверс
Хеннинг Маллвитц
Рикарда Майер
Кристоф Виллерс
Original Assignee
Альмиралль, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Альмиралль, С.А. filed Critical Альмиралль, С.А.
Publication of EA201291335A1 publication Critical patent/EA201291335A1/ru
Publication of EA022967B1 publication Critical patent/EA022967B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Описываются фармацевтические композиции для местного применения, содержащие по отношению к общей массе композиции: а) 0,01-0,2 мас.% мометазона фуроата, b) 5-18 мас.% гексиленгликоля, с) 20-40 мас.% воды и d) 25-70 мас.% масляной фазы. Указанные композиции являются стабильными и могут безопасно и легко наноситься на большие площади поверхности кожи приемлемым путем для популяции пациентов в целом с целью лечения или предотвращения псориаза, атопического дерматита (атопической экземы) и других расстройств или заболеваний кожи.
EA201291335A 2010-05-26 2011-05-13 Фармацевтическая композиция для местного применения, содержащая суспендированный мометазона фуроат EA022967B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382146A EP2394653A1 (en) 2010-05-26 2010-05-26 Topical pharmaceutical compositions comprising mometasone furoate
US36505010P 2010-07-16 2010-07-16
PCT/EP2011/002369 WO2011147536A2 (en) 2010-05-26 2011-05-13 Topical pharmaceutical compositions

Publications (2)

Publication Number Publication Date
EA201291335A1 true EA201291335A1 (ru) 2013-04-30
EA022967B1 EA022967B1 (ru) 2016-03-31

Family

ID=42797321

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291335A EA022967B1 (ru) 2010-05-26 2011-05-13 Фармацевтическая композиция для местного применения, содержащая суспендированный мометазона фуроат

Country Status (33)

Country Link
US (2) US20140200203A1 (ru)
EP (2) EP2394653A1 (ru)
JP (1) JP5743241B2 (ru)
KR (1) KR101790371B1 (ru)
CN (1) CN102883725B (ru)
AR (1) AR081765A1 (ru)
AU (1) AU2011257586B2 (ru)
BR (1) BR112012030006A2 (ru)
CA (1) CA2794553C (ru)
CL (1) CL2012003282A1 (ru)
CO (1) CO6640244A2 (ru)
DK (1) DK2575822T3 (ru)
EA (1) EA022967B1 (ru)
ES (1) ES2595250T3 (ru)
HK (1) HK1177893A1 (ru)
HR (1) HRP20161288T1 (ru)
HU (1) HUE029818T2 (ru)
IL (1) IL222163B (ru)
LT (1) LT2575822T (ru)
ME (1) ME02555B (ru)
MX (1) MX2012013642A (ru)
MY (1) MY160377A (ru)
NZ (1) NZ602730A (ru)
PL (1) PL2575822T3 (ru)
PT (1) PT2575822T (ru)
RS (1) RS55233B1 (ru)
SG (2) SG184405A1 (ru)
SI (1) SI2575822T1 (ru)
SM (1) SMT201600342B (ru)
TW (1) TWI473615B (ru)
UY (1) UY33404A (ru)
WO (1) WO2011147536A2 (ru)
ZA (1) ZA201208420B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
KR20160030162A (ko) * 2013-07-11 2016-03-16 가부시키가이샤 폴라 파마 사용시 거품상을 나타내는 외용 조성물
GB2540764A (en) * 2015-07-24 2017-02-01 Fontus Health Ltd Topical composition
KR20190138790A (ko) * 2017-03-10 2019-12-16 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 유출 펌프 억제제로서의 인돌 유도체
EP3492068A1 (en) * 2017-12-01 2019-06-05 NCP NewCare Products GmbH Composition for treating onychomycosis
CN114767630A (zh) * 2022-06-06 2022-07-22 黑龙江中医药大学 一种治疗变应性鼻炎的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808610A (en) 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
US5422361A (en) 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
TW442281B (en) 1993-12-21 2001-06-23 Schering Corp Pharmaceutical compositions for treating psoriasis and other hyperkeratotic and/or scaly dermatoses
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
EP1033991B1 (en) 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
TR200201343A2 (tr) 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
CA2532707A1 (en) 2003-05-23 2004-12-09 Taro Pharmaceuticals U.S.A., Inc. Novel topical steroid cream formulations
DE102006034883A1 (de) 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
WO2008126076A2 (en) 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate

Also Published As

Publication number Publication date
LT2575822T (lt) 2016-10-10
MX2012013642A (es) 2013-05-06
SMT201600342B (it) 2017-01-10
AU2011257586A1 (en) 2012-11-01
CO6640244A2 (es) 2013-03-22
CN102883725A (zh) 2013-01-16
RS55233B1 (sr) 2017-02-28
AR081765A1 (es) 2012-10-17
UY33404A (es) 2011-12-01
WO2011147536A3 (en) 2012-06-07
EA022967B1 (ru) 2016-03-31
BR112012030006A2 (pt) 2016-08-02
ES2595250T3 (es) 2016-12-28
SG184405A1 (en) 2012-11-29
PT2575822T (pt) 2016-10-06
ME02555B (me) 2017-02-20
EP2575822B1 (en) 2016-07-06
CN102883725B (zh) 2015-04-01
CA2794553C (en) 2018-01-02
PL2575822T3 (pl) 2017-01-31
EP2575822A2 (en) 2013-04-10
KR20130086137A (ko) 2013-07-31
AU2011257586B2 (en) 2014-04-17
ZA201208420B (en) 2013-09-25
US20160038512A1 (en) 2016-02-11
IL222163B (en) 2018-01-31
NZ602730A (en) 2014-03-28
CL2012003282A1 (es) 2013-01-25
HUE029818T2 (en) 2017-04-28
WO2011147536A2 (en) 2011-12-01
HRP20161288T1 (hr) 2016-11-18
TW201204367A (en) 2012-02-01
US9907807B2 (en) 2018-03-06
SI2575822T1 (sl) 2016-11-30
DK2575822T3 (en) 2016-10-17
JP2013530149A (ja) 2013-07-25
US20140200203A1 (en) 2014-07-17
SG10201502252YA (en) 2015-05-28
HK1177893A1 (zh) 2013-08-30
MY160377A (en) 2017-03-15
KR101790371B1 (ko) 2017-10-25
JP5743241B2 (ja) 2015-07-01
CA2794553A1 (en) 2011-12-01
TWI473615B (zh) 2015-02-21
EP2394653A1 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
MX2020012595A (es) Composiciones farmaceuticas topicas.
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
DOP2013000105A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
EA201291108A1 (ru) Фармацевтические композиции в виде эмульсии с низким содержанием масла, содержащие прогестоген
EA201291335A1 (ru) Фармацевтические композиции для местного применения
CL2016000188A1 (es) Composiciones de arní de serpinc1 y métodos de uso de las mismas
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
EA201291310A1 (ru) Композиция ингибитора jak для местного применения
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
AR084197A1 (es) Composicion para uso topico para el tratamiento de trastornos de la piel
TR201903470T4 (tr) Kişisel hijyen için formülasyon.
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
PH12015501538A1 (en) Topical ocular analgesic agents
NI201200196A (es) Agentes terapéuticos 976
EA201992547A1 (ru) Композиции для местного ухода за кожей
TH153704A (th) องค์ประกอบทางเภสัชกรรมสำหรับใช้เฉพาะที่
MX366038B (es) 1, 2-dioles y 1,2,3-trioles antiespasmodicos.
PL404379A1 (pl) Maść
FR2975003B1 (fr) Composition cosmetique topique presentant une penetration amelioree
WO2012095500A3 (en) Pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU